Glucagon and Glucagon-Like Peptides

Product #


Biochem/physiol Actions

Add to Cart

G1774 Glucagon ≥95% (HPLC), powder, synthetic Glucagon (GCG) produces elevation in contractility and the frequency of contraction in heart muscles. It activates PI3K (phosphoinositide 3-kinase) and thus, elevates glucose utilization by heart muscles. In multiple mammals, though not humans, this peptide induces lipolysis, and is the major lipolytic hormone in birds. It also induces gluconeogenesis and glycogenolysis in mammals and birds.
G2654 Monoclonal Anti-Glucagon antibody produced in mouse clone K79bB10, ascites fluid  
G8147 Glucagon-Like Peptide I Amide Fragment 7-36 human ≥97% (HPLC), powder GLP-1 (glucagon-like peptide 1) (7-36) amide is a potent insulinotropic peptide, which initiates the glucose-induced insulin release after meals or oral glucose intake. It has an anti-diabetogenic effect and thus, might have use in the treatment of non-insulin dependent diabetes mellitus.
G8166 Glucagon-Like Peptide 2 -Arg human trifluoroacetate salt >90% (HPLC), solid Glucagon-like peptide 2 (GLP-2) influences the functionality of gastrointestinal tract by participating in the feedback loop to the brain for the control of food intake. It also controls digestion and absorption, and has tropic effects post chemotherapy injury or surgical resection. This peptide is also responsible for epithelial cell proliferation of the small bowel. Studies in rats show that this peptide enhances the effects of the ileal-brake hormones, GLP-1 and peptide YY. It also negatively regulates gastrointestinal motility and secretion. Thus, it has potential as a therapeutic agent in short-bowel syndrome.
Glucagon-like peptide 2 is a neuropeptide that inhibits food intake when injected into the lateral ventricles of the brain and may mediate satiety. It is also a growth factor that stimulates proliferation and blocks apoptosis of intestinal epithelial cells.
G9416 Glucagon-Like Peptide 1 Fragment 7-37 human ≥96% (HPLC)  
G3265 Glucagon-Like Peptide I human ≥97% (HPLC) Glucagon-Like Peptide I (GLP1) controls the metabolism of glucose, by inducing the secretion of insulin and suppressing that of glucagon. Studies in Indonesian population show that reduced levels of this protein are linked with increased susceptibility to type 2 diabetes mellitus. Plasma levels of this hormone also show significant association with systolic and diastolic blood pressure levels.